Solid Tumor Market

Solid Tumor Market Size (2023 to 2028)

The global solid tumor market size is expected to grow at a CAGR of 18.86% during the forecast period. 

Solid tumors are formed due to the aggregation of abnormal tissues that do not comprise cysts or liquid areas. They are mainly of two types- malignant and benign. Most solid tumors are treated via radiotherapy, chemotherapy, or surgery. Various chemotherapeutic drugs are available in the market, along with a ripe pipeline of drugs that will soon be commercialized.

MARKET DRIVERS:

The growing cancer patient population worldwide and the rising incidence of several solid tumor cases are majorly driving the global solid tumor market growth.

The American Cancer Society estimated that there were an estimated 1.9 million new cancer cases and 608,570 deaths in 2021. Due to the increase in cancer cases, there has been an increasing demand for highly effective chemotherapeutic agents, which drives the global solid tumor market. Many companies are investing in R&D projects related to therapeutics, which fuels the market growth. An increase in demand for highly effective chemotherapeutic agents and the ripe availability pipeline of drugs in the global market is expected to propel the substantial tumor market. Lung, colorectal, liver, and breast cancers are spreading enormously; as per the records, approximately 8.2 million people died; this is expected to increase during the forecast period. Major drugs such as Afinitor (Everolimus), Tarceva (erlotinib), Taxotere (docetaxel), Doxorubicin, and (Avastin bevacizumab) are available in the global market and being utilized in clinical trials are expected to boost the market growth. These products will soon be commercialized globally and further augment the market growth. Moreover, rising government initiatives to create cancer awareness among the people and increase healthcare infrastructure influence market growth.

Increasing radiation exposure also drives the solid tumor market forward.

These solid tumor cases are seen primarily in bomb survivors. There is an increase in the risk of cancer due to the late effect of radiation exposure seen in A-bomb survivors. This solid tumor occurs in patients after ten years of exposure to harmful radiation. This was first noted by a Japanese physician Gensaku Obo by researching analyses of cancer mortality in Hiroshima and Nagasaki-affected people. Additionally, advancements in the treatment techniques, such as targeted and combination therapies that include Kadcyla and Herceptin for breast cancer, provide growth opportunities for the solid tumor market. Either as a single agent or as a combination, the safety profile of vaccines represents excellent opportunities. The rise in cancer people is lucratively fuelling the solid tumor market demand. Government initiative steps are also additionally accelerating the growth of this market.

MARKET RESTRAINTS:

However, increasing generic products, the high cost of therapy, the rising cost of R&D, and various drugs going off-patent, are turning out to be restraints for the global solid tumor market. In addition, stringent government regulatory reforms over solid tumors and generic competition lead to price erosion, hindering solid tumor market growth over the forecast period.

Impact of COVID-19 on the global solid tumor market:

The World health organization proclaimed the spread of the virus to be a pandemic, and COVID-19 is an infectious disease caused by the most recent novel coronavirus, which transmits quickly from person to person. COVID-19 was first identified in Wuhan, China. COVID-19 first arrived as a regional pandemic and turned into a global pandemic. Due to a sudden surge in virus transmission, the world health organization announced specific guidelines to stop the virus's spread. Governments imposed nationwide lockdowns and a flight ban to spread the migrants from foreign countries.

The unexpected emergence of COVID-19 has positively and negatively impacted the pharmaceutical and medical device industries. In addition, the effects of the pandemic and the winding down of the worldwide science market have harmed the operations and financial results of many industry participants, such as solid tumors.

During the first quarter of 2020, the solid tumor market had a growth decline because of the surge in virus prevalence and the nationwide lockdown. During the outbreak, the nation focused on combatting the virus. As a result, solid testing tumor procedures have been postponed as the rise in the covid-19 cases. In addition, solid tumor treatment had not been performed due to the unavailability of healthcare professionals.

However, the uplift of the lockdown has increased the market growth due to the resumed reliable tumor procedures. The hospitals started treating cancer patients. The chemotherapy market is currently holding the global market with a dominant share. However, the solid tumor market is projected to grow better in the coming years.

REPORT COVERAGE:

This market research report on the global solid tumor market has been segmented and sub-segmented based on the disease, drugs, and region.

Solid Tumor Market - By Disease:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Cervical Cancer
• Others

Based on disease type, breast cancer and prostate cancer are expected to contribute the most significant share value due to the increasing occurrence rates of the diseases. In 2020, nearly 2.5 million women were diagnosed with breast cancer globally. People who are aged above 40 years will affect by this breast cancer. Factors such as obesity, harmful use of alcohol, family history of breast cancer, history of radiation exposure, and reproductive history are all caused due to increase in breast cancer cases. In addition, increasing these cases increases the treatment for solid tumors, which drives the market forward.

Prostate cancer is the most common cancer among men. Nearly an estimated 270,000 men in the United States have undergone diagnosis every year. The FDA has approved a drug called Pluvicto, a new radiation pharmaceutical in 2022, administered through injection or infusion. This drug travels throughout the body and targets cancer cells with the PSMA biomarker. Then the radiation is released to damage and kill cancer cells. Other treatments such as hormone therapy, chemotherapy, radiation, and surgery are the other options for prostate cancer. In the present situation, surgery is mainly the preferred treatment for solid cancer tumors. Chemotherapy is one of the preferred surgeries, as other modes like radiation.

Solid Tumor Market - By Drugs:

• Carboplatin

• Cisplatin
• Gemcitabine
• Paclitaxel
• Doxorubicin
• Bevacizumab
• Erlotinib
• Sunitinib
• Everolimus
• Docetaxel
• Abiraterone
• Abiraterone acetate
• Cabazitaxel

The cisplatin segment has the highest market share. It is the drug used in chemotherapy to treat testicular, ovarian, bladder, head and neck, lung, cervical Cancer, and other types of cancers. Once the drug enters the cell, Cisplatin starts to cause cytotoxicity by losing one chloride ligand, binding to DNA to create intra-strand DNA adducts, and preventing DNA synthesis and cell development. However, the cancer patients who use this drug are having good progress in health improvement, which drives the segment growth forward.

Doxorubicin is another segment that drives the market forward. This drug is used in chemotherapy for patients suffering from solid tumors. It helps to stop or reduce the growth of the cancer cell in the body by blocking an enzyme called topo isomerase.

The cabazitaxel segment also drives the market growth due to increasing cases of the prostate in men. It is an injection that is given together with a steroid medicine to treat men with metastatic castration-resistant prostate cancer.

Solid Tumor Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The global solid tumor market was dominated by North America, followed by Europe. However, Asia Pacific is a lucrative market and is expected to grow at a high CAGR. The North American solid tumor market is anticipated to dominate the global market throughout the forecast period. The factors driving the market are the high occurrence rate of solid cancer cases with well-equipped healthcare infrastructure. Following North America, Europe is ruling with dominant shares of the market. Cancer is the leading cause of death in Canadian people. As per the survey, 2 in 5 Canadians are diagnosed with any of the cancers in their lifetime. Breast, lung, and prostate cancer are the most common cancer in many people. The government also launches different therapy and treatment for people for the reduction or prevention of Cancer which drives the market growth in this region.

The solid tumor market in Asia-Pacific is anticipated to have the fastest growth due to the rapidly developing medical infrastructure, rising medical tourism, and increased expenditure. Countries like India and China are creating awareness over the availability of treatment procedures, setting up growth opportunities for market growth. Lung cancer and breast cancer are the most common cancer cancers in China. Breast cancer is the most frequent cancer type among women, resulting in solid tumor therapy for reducing cancer cells in the body. China's government is focusing on improving cancer treatment for the prolonged survival of the China People. As a result, hospitals in China bind on to give safe and effective treatment to decrease the death rates in China. For the past 20 years, Cancer has been the leading cause of death in Japan, and the death rate is increasing yearly. Factors such as tobacco smoking, alcohol drinking, and unhealthy diet are a few reasons for the attack of Cancer in the people who lived in Japan. The healthcare system in Japan produces some of the best treatments compare to the other countries in the world. Cancer survivors are more in Japan due to the quality treatment given to the people. The Japanese government has implemented several policies for the treatment of cancer patients and to increase the survivor percentage. Japan's government also increases awareness programs by making people aware of solid tumor treatments and increasing the life span of the people. Therefore, the region's market has the highest growth.

The solid tumor market in the European region also has a significant share in the market growth. According to a recent survey, nearly 4 million cases have been noticed in recent years in Europe. As a result, the E.U. government has allowed different types of advanced solid tumor therapy for Cancer to reduce the cancer cases in this region.

The Latin American solid tumor market is expected to showcase steady growth during the forecast period.

The solid tumor market in the Middle East and Africa is anticipated to register a moderate CAGR during the forecast period.

KEY MARKET PARTICIPANTS:

Key market participants leading the global solid tumor market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi.

KEY HAPPENINGS IN THIS MARKET:

• In 2022, Solid tumors use a type of T cell as a shield against immune attack. Target antigen identification, efficient transport to the tumor, robust activation, proliferation, and in vivo cytotoxicity are all features of CAR T-cell therapy for solid tumors.
• In 2021, the Food and Drug Administration approved sotorasib (Lumakras, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer.
• In January 2020, Amgen publicly stated that it would collaborate with two business-lading diagnostic companies, Guardant and QIAGEN N.V., to develop blood tissue companion diagnostics. The agreement between the companies will focus on non-small cell lung cancer treatment procedures.
• In March 2020, the liver cancer drug officially received approval from the FDA, which Bristol-Myers Squibb Company introduced.
• In June 2019, Roche publicly stated that the combination of Tecentriq, Avastin, carboplatin, and paclitaxel showed positive results in patients suffering from liver metastases.
• In December 2019, two major companies, Innovent and Eli Lilly and Company, collectively presented their Tyvyt. The medicine works to restore the patient's tumor T-cell response. The result between the two companies provides patients with effective and protected treatment solutions to fight against cancer.